Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 20/20 | 0.79 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.79 |
| ▸ | HTR1A | P08908 | 9/20 | 0.79 |
| ▸ | HTR1B | P28222 | 11/20 | 0.76 |
| ▸ | DRD2 | P14416 | 4/20 | 0.55 |
| ▸ | HTR2A | P28223 | 3/20 | 0.55 |
| ▸ | DRD4 | P21917 | 1/20 | 0.55 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6811955 | 0.95 | HTR1D (0.80) | HTR1DSLC6A4HTR1AHTR1BDRD2 | |
| SCHEMBL6816636 | 0.90 | HTR1D (0.85) | HTR1DSLC6A4HTR1AHTR1BDRD2 | |
| SCHEMBL6812851 | 0.89 | HTR1D (0.74) | HTR1DSLC6A4HTR1AHTR1BDRD2 | |
| SCHEMBL6808227 | 0.88 | HTR1D (1.00) | HTR1DSLC6A4HTR1AHTR1BDRD2 | |
| SCHEMBL6811270 | 0.86 | HTR1D (0.74) | HTR1DSLC6A4HTR1AHTR1BDRD2 | |
| SCHEMBL6811543 | 0.86 | HTR1D (1.00) | HTR1DSLC6A4HTR1AHTR1BDRD2 | |
| SCHEMBL6808342 | 0.84 | HTR1D (0.75) | HTR1DSLC6A4HTR1AHTR1BDRD2 | |
| SCHEMBL6812166 | 0.84 | HTR1D (0.79) | HTR1DSLC6A4HTR1AHTR1BDRD2 | |
| SCHEMBL6808283 | 0.84 | HTR1D (0.75) | HTR1DSLC6A4HTR1AHTR1BDRD2 | |
| SCHEMBL6816614 | 0.83 | HTR1D (0.84) | HTR1DSLC6A4HTR1AHTR1BDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040122001-A1 | Pharmaceutical compounds | ELI LILLY AND COMPANY | 2004-06-24 | — | — | US | disclosed |
| WO-2004005298-A1 | DERIVATIVES OF RIFABUTINE USEFUL AS ANTIMICROBIAL AGENTS | INSTITUTO NACIONAL DE ENGENHARIA E TECNOLOGIA INDUSTRIAL (PT) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122001-A1 | Pharmaceutical compounds | CYP2D6, LPXN, CYP1B1 | HTR1D 124/4885SLC6A4 1958/4885HTR1A 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.